Don't Qualify for a GLP-1? 5 Online Options [2026]

By the Weight Loss Provider Guide Research Team · Last verified: August 28, 2026

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We earn a commission from some links on this page. That commission did not change a single row in any table below.

If you don't qualify for a GLP-1, the first thing to find out is who told you no — because a "no" can come from five different places, and those decisions do not mean the same thing.

An intake form, a clinician, the FDA label, your insurance company, and your pharmacy all use the same word. They mean five different things. Four can often be revisited. A true label contraindication is not fixed by changing websites.

Here's the part almost nobody tells you: the current FDA labels for Wegovy, Zepbound, and Foundayo each list two contraindication categories. All three bar use with a personal or family history of medullary thyroid carcinoma, or MTC, or Multiple Endocrine Neoplasia syndrome type 2, or MEN 2. Each also bars use after a serious hypersensitivity reaction to that drug or one of its ingredients. The thyroid rule is class-wide across these three. The allergy rule is tied to the exact drug.

Everything else needs to be sorted into the right bucket: labeled indication, warning, clinician judgment, company workflow, insurance contract, or pharmacy claim. Some can move. Some deserve a specialist. None should be blurred together.

So before you fill out another form and pay another fee, spend four minutes figuring out which "no" you actually got. We built the table below to do exactly that.

Start here: which "no" did you get?

Answer capsule: A GLP-1 rejection can come from one of five sources: an automated intake screen, a licensed clinician, an FDA label contraindication, an insurance plan, or a pharmacy claim. A true label contraindication is not fixed by switching companies. The other four are tied to one platform, one clinical review, one plan, or one claim — but that does not mean every "no" should be overturned.

👉 Not sure which one you got?

Match your "no" to the right next step → No prescription promised. You will get a plain-English path for the gate that stopped you.

What should you do first if you don't qualify for a GLP-1?

Answer capsule: The first step is to get the exact reason in writing and confirm whether a licensed clinician reviewed your full history or an automated screen stopped you first. Applying to more providers before you know which decision was made wastes money, because a second platform cannot fix an insurance exclusion, a pharmacy claim problem, or a true label contraindication.

Four steps. In this order.

Step 1 — Find out who decided. If it was instant and no named clinician contacted you, software probably stopped the process first. Did a named clinician message you? That was a clinical decision. Did you get a letter or a claim code? That was insurance or the pharmacy.

Step 2 — Get the reason in writing. Copy this and send it to the platform:

"Please send me the exact reason my request was declined, and tell me whether that decision came from your automated screening, a licensed clinician, my insurer, or the pharmacy."

That one sentence is the most valuable thing on this page. Everything downstream depends on the answer.

Step 3 — Match the reason to the right path. Use the table above, then the rejection router below.

Step 4 — Do not change your answers.

We have to be blunt here. It is tempting to shave an inch off your height or add ten pounds, or to leave out a diagnosis that got you kicked out.

Don't. Not because we're scolding you — because the exact details that trigger a rejection are usually the ones a clinician needs to keep you safe. A form that says no because you mentioned a prior serious reaction is doing its job. Fix a real error, sure. Recheck your height without shoes. Use a scale that works. But don't invent a person who doesn't exist.

Why did the online GLP-1 provider reject you?

Answer capsule: Online platforms can use automated rules before or alongside clinician review. Platforms set their own workflow limits, state availability, age limits, and medication flags. An instant screen-out before a named clinician contacts you is not the same as a clinician reviewing your full record — but it can still be triggered by a real safety issue.

Here's what can happen behind that screen.

You answer a health questionnaire. Software checks your answers against rules the company wrote. If an answer trips a rule, the process may stop before a named clinician reviews your file.

Common trip-wires that may be platform rules, workflow limits, or safety flags:

• Your current BMI, with no place to enter what it was before treatment
• Your state isn't one the platform currently serves
• The platform's upper or lower age cutoff
• A medication on its auto-flag list
• An answer it reads as "needs a live visit," which that workflow does not offer
• A blank or unclear field that prevents the intake from moving forward

None of that proves a GLP-1 is wrong for you. It tells you that this platform stopped. The reason still matters.

But — and this matters — an instant rejection isn't automatically wrong, either. Sometimes the form catches something real, fast. The point isn't that the form is your enemy. The point is that the form answered a narrow question, and you deserve to know which question it answered.

What people actually say when this happens

We pulled these from public forums. They're here to show you that the confusion is normal — not as medical evidence, and not as a claim about what any treatment does.

"DID NOT QUALIFY WITH BMI 27… what should i do now?" — r/tirzepatidecompound. The same person said the consultation felt wasted, and that they "feel so dumb."

"Some places immediately rejected me because my BMI wasn't 'high enough.' It was super frustrating." — r/glp1

"All he told me was to work out more and harder." — r/Semaglutide, describing a doctor's refusal with no explanation

If you felt small reading your rejection screen, you're in a very large group. Nothing about that message was a verdict on you.

👉 A form is not a clinician

If nobody reviewed your actual history, that's worth fixing before you spend another dollar. See if a licensed provider review changes your answer — check eligibility with Ro → Ro says it charges $39 for month one, refunds that $39 if you are not eligible for GLP-1s, and then charges $74–$149 per month depending on the plan. Medication is separate. A licensed provider still decides whether treatment is appropriate.

What actually disqualifies you from a GLP-1?

Answer capsule: The current FDA prescribing information for Wegovy, Zepbound, and Foundayo lists two contraindication categories for each drug: a personal or family history of medullary thyroid carcinoma, or MEN 2, and a prior serious hypersensitivity reaction to that exact drug or its ingredients. MTC or MEN 2 applies across all three. A serious reaction to a different GLP-1 calls for caution and clinician review; it is not automatically the same product-specific contraindication.

This is the single most misunderstood thing about GLP-1 eligibility, so let's slow down.

An FDA drug label has two different sections that people mix up:

Section 4 — Contraindications. This is the label's do-not-use list. Every legitimate US prescriber is expected to honor it.

Section 5 — Warnings and Precautions. This is where warnings, monitoring instructions, and statements such as "not recommended" live. It is not the same section as Contraindications, but it can still contain a firm reason to stop, avoid treatment, or bring in a specialist.

Now look at how short Section 4 actually is.

Primary sources: Wegovy prescribing information, Zepbound prescribing information, and Foundayo prescribing information. Verified August 28, 2026.

Two categories on all three. One is class-wide across these products. One is tied to the exact drug and its ingredients.

Now here's what is not in Section 4, even though people often hear the word "contraindicated" used for it:

• Pregnancy. It is serious, and it is handled in a different section. The labels direct patients to stop when pregnancy is recognized. Wegovy's label also says to stop at least two months before a planned pregnancy because semaglutide stays in the body a long time. It is still a do-not-use-now situation for weight loss, even though it is not listed in Section 4.
• Severe gastroparesis — a stomach that empties very slowly. The current Wegovy, Zepbound, and Foundayo labels all say the drug is not recommended in patients with severe gastroparesis. That is stronger than a casual warning and is not a reason to shop for a looser form.
• A history of pancreatitis. It is not listed as a contraindication in these three labels. It is a real safety conversation with a real clinician, not an automatic Section 4 bar.
• Gallbladder disease, kidney issues, and diabetic retinopathy. These appear in warnings, precautions, monitoring instructions, or use-specific sections. They require an individual review and may stop treatment in some people.

So if a form used the word "contraindicated" for one of these, ask for the exact reason and the label section. You may not have hit Section 4 — but you may still have hit a serious warning that deserves a careful no.

The intake form asked a bigger question than the FDA label does

Answer capsule: Some online intake forms ask about any "family history of thyroid cancer," while the FDA contraindication applies specifically to medullary thyroid carcinoma, or MTC, and MEN 2. The American Thyroid Association says MTC accounts for about 1%–2% of US thyroid cancers and up to 25% of MTC diagnoses are inherited. The type of thyroid cancer a relative had is the key question.

This is the gap we most want you to see, because it sends people away who may never have hit the label's thyroid rule.

The label bars one specific kind of thyroid cancer. A broad checkbox may only say "thyroid cancer."

Look at the numbers:

And of that small medullary slice, the ATA says up to 25% is inherited.

Sources: ATA overview of papillary and follicular thyroid cancer, ATA medullary thyroid cancer guide, and ATA anaplastic thyroid cancer guide.

Plain version: about 49 out of 50 thyroid cancers are not medullary thyroid cancer. If your aunt had thyroid cancer and a form kicked you out, the single most useful thing you can do this week is find out which kind she had.

How to ask, without making it weird:

"Hey — this is random, but I'm sorting out a medication thing. Do you remember what type of thyroid cancer you had? Was it papillary, follicular, or medullary? The paperwork only matters for one specific type."

Important safety rail: do not clear yourself. Get the actual type from your relative or their records, then give that answer to a clinician and let them decide. If you can't find out, the careful answer stands. We're not telling you to check a different box. We're telling you to go get the real answer, because the first question may have been too broad.

One more thing we found reading the newest label

Foundayo, orforglipron, is the new GLP-1 pill from Eli Lilly. The FDA approved it on April 1, 2026. It carries the same thyroid boxed warning and MTC or MEN 2 contraindication as the injections compared here.

But read what its own boxed warning says: orforglipron "is not pharmacologically active in rats or mice and did not produce tumors in rodents." The label then says it is active at the human GLP-1 receptor, the human relevance has not been determined, and the contraindication remains.

Why this matters to you: the MTC or MEN 2 wall is precautionary and class-wide across these three products. So "just try the new pill instead" is not a workaround. If MTC or MEN 2 is in your personal or family history, this door is closed on all three. Skip ahead to the Open Door Map — a different medicine class may still be worth discussing.

Source: FDA approval announcement and Foundayo prescribing information.

What if a doctor said no?

Answer capsule: A clinician's refusal can mean the treatment appears medically inappropriate for you, key information was missing from the record, or the practice does not manage weight-management medication at all. These are different situations with different next steps, and you can ask which one applies.

There's a huge difference between these two sentences:

• "This medication isn't safe for you."
• "I don't prescribe this."

Both come out of a doctor's mouth as "no." Only the first one is about your body.

Some primary care practices simply don't manage obesity medicine. That's not a safety finding. It's a scope decision. Another qualified clinician can evaluate you.

Ask this exact question:

"Is the reason you're declining this my BMI, a specific health risk, another medication I'm on, missing information, or your practice's policy on prescribing it?"

Five options. One of them is the answer. And whichever one it is, you'll know more in 30 seconds than most people learn in three months.

When a second opinion makes sense:

• The reason was never explained
• Your practice doesn't handle weight-management medication
• Records from prior treatment weren't available
• A diagnosis you actually have wasn't in the chart
• You want to talk to someone who treats obesity all day

When it doesn't:

• The clinician named a specific safety concern and explained it
• You'd have to leave something out to get a different answer

If you want a specialist rather than another telehealth platform, the Obesity Medicine Association keeps a public clinician directory. It costs us nothing to tell you that, and for a complicated history it may be the better move.

👉 Want a real conversation, not another form?

If your first "no" came with no explanation, a live video visit lets you talk it through — and you pick the clinician. Choose a clinician and check availability in your state — Sesame → A visit is a medical evaluation, not a prescription guarantee. Sesame says prescriptions are at the provider's discretion. For its weight-loss program, it states that you can cancel at least 3 hours before your first visit for a full refund; after the first visit happens, the first month is not refundable.

What if your BMI was the reason?

Answer capsule: The standard adult weight-management indication generally begins at a BMI of 30 or higher, or 27 or higher with at least one documented weight-related condition. A current BMI below that range means something different when prior prescribed treatment caused the decrease, because that is a continuation-of-care question rather than a new-start request.

Three situations, three different answers. Find yours.

1. Your BMI is 27–29.9 and no related condition is in your chart. You may be closer than you think. The 27 door opens with one documented weight-related condition — and some people discover one only after proper screening. High blood pressure. Prediabetes. High cholesterol. Sleep apnea nobody screened for.

The honest version: you need a real diagnosis, documented by a clinician who evaluated you. Not a suspicion. Not a symptom you googled. Go get screened properly — blood pressure readings, A1C, a lipid panel, a sleep screen if you snore. If something's there, it's there and it should be treated on its own merits. If nothing's there, that's good news about your health, even if it's not the news you wanted today.

2. Your BMI is under 27 and you've never used a GLP-1. We're going to be straight with you: this is outside the standard labeled adult weight-management indication right now, and we're not going to point you at a company that will wave you through anyway. That's not gatekeeping. A routine new start below the labeled threshold has not been established by these obesity labels. Talk to a clinician about what would help. That's a real conversation worth having.

3. Your BMI is lower because the medicine worked. This one gets handled wrong constantly, and it's the most fixable.

You started at 34. You're at 28 now because treatment did its job. A form asked for today's number, never asked for your starting number, and rejected you — for succeeding.

That's a continuation question being processed as a new-start question. The NIDDK says FDA-approved long-term weight-management medications can be continued as long as a person is benefiting and not having serious side effects. Your clinician still decides whether continuing is right for you.

What fixes it is paperwork, not persuasion:

• Your pretreatment weight and BMI, with a date
• The original qualifying diagnosis
• When treatment started, and the dose history
• Prescription or pharmacy records
• How you responded, and any side effects
• Whether related conditions improved

Put that in one document. Then ask the question that unlocks it: "Did the submission include my pretreatment BMI and treatment history, or just today's number?"

More detail on the BMI-specific paths is in our GLP-1 BMI eligibility guide. For the paperwork path, see how to get a GLP-1 approved for weight loss.

What if insurance was the one that said no?

Answer capsule: Insurance denials fall into different lanes. A denial involving medical judgment may be eligible for internal appeal and then independent external review, depending on the plan and state. A pure benefit exclusion is usually a contract question rather than a medical one, so medical external review is often not the right path. The denial notice tells you which rules and deadlines apply.

Read your denial letter. Look for which of these two things it says. This changes everything.

HealthCare.gov says external review covers denials that involve medical judgment, experimental or investigational treatment decisions, and certain coverage cancellations. It also says you usually have four months after the final denial to request external review. Your own denial notice controls the exact route and deadline.

KFF's 2024 HealthCare.gov data shows why the wording matters: only 5% of reported in-network denials were labeled lack of medical necessity, while many more were administrative or placed in an "other" category. Do not assume every denial fits the same appeal lane.

So:

• "Not medically necessary" or "criteria not met" → use the appeal instructions and build the record.
• "Not a covered benefit" → verify the exclusion and ask what contract, employer, grievance, or enrollment options exist. Do not keep sending the same medical appeal to a plan that excludes the benefit.

Sources: HealthCare.gov external-review guide, CMS external-appeals overview, and KFF's 2024 claims-denial analysis.

"You skipped a step" is not "you don't qualify"

Here's a denial reason that reads like rejection but is actually a to-do list.

Two historical 2025 MassHealth appeal decisions show how missing step-therapy documentation can sink a request. In one, the plan said phentermine was the preferred weight-loss drug and required either a medical reason it could not be used or a documented poor response. In another, the member had tried phentermine, but the required fact was not shown on the form.

Those decisions are useful because they show the paperwork failure. They are not current rules for every plan. MassHealth later announced that a phentermine trial would no longer be required before a weight-loss GLP-1 beginning in 2026. Your plan's current written criteria are the only criteria that count today.

Sources: Massachusetts Appeal No. 2504819, Appeal No. 2506857, and the January 2026 MassHealth update.

That's not a medical verdict. That's a missing box on a form.

Ask your insurer this, word for word:

"Please give me the exact denial reason, the denial code, your written coverage criteria, the appeal deadline, and the criteria for continuation as opposed to a new start."

👉 If your plan is the problem, don't fight it blind

Insurance paperwork is the single most fixable "no" on this page — and the most tedious. Check your GLP-1 coverage free before you pay for a program — Ro → Ro's free checker produces a coverage report and does not submit a treatment request or write a prescription. If you enroll in Ro Body and prior authorization is needed, Ro says its insurance concierge submits the paperwork and may file an appeal after a denial. Ro charges $39 for month one, then $74–$149 per month depending on the plan. Medication is separate.

What if the pharmacy said no?

Answer capsule: A pharmacy rejection is a claim-processing result, not a medical decision. Common causes include prior authorization, stock, refill timing, quantity limits, network rules, formulary status, or a prescription that needs clarification. The exact rejection message or code tells you which one applies.

You had a valid prescription. You went to pick it up. The screen said denied. Your stomach dropped.

Here are six common causes, and most are not a new medical eligibility decision:

The one thing to say at the counter:

"What exact claim rejection message or code came back, and should my prescriber or my plan be the one to fix it?"

Write the code down. Send it to your prescriber. Do not start a new intake at a new telehealth company over a pharmacy claim code. You could pay again to solve a problem that was never about your medical eligibility.

Will another online provider just say yes?

Answer capsule: Another licensed review can make sense when the first decision came from an automated screen, missing records, a practice that does not prescribe weight-management medication, or a continuation issue processed as a new request. It is not a safe strategy when the first decision identified MTC or MEN 2, a product-specific serious allergy, or another explained safety concern.

Sometimes yes. And it's not automatically a loophole — different companies genuinely have different workflows, state coverage, and medication menus. A no from Company A can be a Company A decision.

But here's our one honest admission, and we'd rather lose you than skip it:

Ro will not prescribe a GLP-1 if the label rules out that product. Ro charges $39 for month one and says it refunds the $39 if you are not eligible for GLP-1s. That is not a prescription promise. It is a provider review with a published refund rule. A company that approves you only because you hid the history another clinician flagged has not solved the risk. It has failed to evaluate it.

And if you are the person the GLP-1 label rules out — you're not stuck, and we're not sending you away. The next section is for you, and it's the most useful thing on this page.

If a GLP-1 really is closed to you, here's what's still open

Answer capsule: A GLP-1 contraindication does not close every prescription weight-management option. Contrave, Qsymia, and Xenical are FDA-approved for chronic weight management and do not carry the MTC or MEN 2 contraindication found in the GLP-1 labels compared here. Each has its own separate contraindications, warnings, interactions, and pregnancy rules.

We assembled this table by reading six current prescribing labels side by side. Verified August 28, 2026.

Read it as a conversation map, not a prescription. It tells you which door may be worth asking a clinician about. It does not tell you what to take or whether two weight-loss drugs should be combined.

Legend: ❌ = the label says do not use or discontinue · ⚠️ = warning, "not recommended," or clinician/specialist review · ◻️ = not listed as a contraindication in that product's label, but full review is still required

Primary label sources: Wegovy, Zepbound, Foundayo, Contrave, Qsymia, and Xenical.

What these three actually do, in plain words

Contrave — two older medicines combined, naltrexone and bupropion. Nonclinical studies suggest they act on brain pathways tied to appetite and reward, although the exact weight-loss effect is not fully understood. It is not a GLP-1 and does not carry the MTC or MEN 2 warning.

Qsymia — phentermine plus topiramate. It turns appetite down and can make fullness last longer. It is a Schedule IV controlled substance. Because of fetal risk, it is distributed through a REMS program and only certified pharmacies may dispense it.

Xenical or orlistat — works in your gut, blocking some of the fat you eat from being absorbed. Its common gut side effects can get worse after a high-fat meal, which some people find is its own kind of accountability. A lower-dose version, Alli, is available over the counter.

The honest part: their separate trials generally show less average weight loss than the newer GLP-1 medicines. These are not head-to-head comparisons, but nobody should pretend the gap is not there. And "less than Zepbound" and "nothing" are very different things. If the GLP-1 class is closed to you, this is a real treatment path — not a consolation prize.

👉 If GLP-1s are off the table, this is your door

Some GLP-1 telehealth programs only offer GLP-1s. If that's all they have, they have nothing for this branch. Discuss a non-GLP-1 option with a clinician on Sesame → We're routing you here for a specific reason: Sesame publishes pages for Contrave and orlistat, and you choose a clinician for a live video visit. A prescription is never guaranteed. Ro's current weight-loss menu is built around FDA-approved GLP-1 options, so it is not the fit for this branch.

What happens to your money if they say no?

Answer capsule: Charge timing and refund rules differ sharply between telehealth platforms. Ro charges $39 and states that it refunds that amount if you are not eligible. Yucca places a temporary authorization hold and says it does not charge if no prescription is issued. Sesame treats a completed first visit as a delivered service. Embody's own refund page contains wording that points in two directions, so get its rule in writing before paying.

This is the question everybody has and almost nobody answers. "I paid for the consultation and got nothing" is one of the most common things rejected patients say.

So we went and read the terms.

Provider-stated policies checked August 28, 2026: Ro pricing, Yucca FAQ and refund policy, Sesame weight-loss program terms, and Embody refund policy. We did not complete a purchase or test a refund transaction. Policies can change.

We want to be straight about that last row. Embody is a company we work with, and we're pointing at a conflict in its own refund wording rather than picking whichever sentence sounds better. If a page won't tell you that, ask yourself what else it isn't telling you.

Five questions to ask before you enter a card number

1. Will my card be charged, or just authorized, before a clinician approves me?
2. Is the visit itself refundable if no prescription is written?
3. At what exact point is the medication considered "ordered"?
4. How do I cancel, and how much notice do I need?
5. Does a medical disqualification trigger an automatic refund, or a discretionary one?

Screenshot the answers. Policies move.

👉 If your real fear is losing another fee

That fear is reasonable, and one workflow is built around it. Start an intake where the charge follows provider approval — Yucca Health → Yucca says it places a temporary authorization hold and does not charge if no prescription is issued. Yucca offers compounded semaglutide and tirzepatide, which are not FDA-approved finished products. If you want an FDA-approved medication instead, use the Ro path.

Which online option fits your reason for being rejected?

Answer capsule: The right next step depends on which gate produced the rejection. Insurance denials, automated screen-outs, continuation-of-care issues, payment-timing fears, pharmacy claim problems, and true label contraindications lead to different routes. Some rejection types should not lead to another telehealth provider at all.

There is no single winner on this page. Find your row.

What to say next: four scripts you can copy

Answer capsule: The most useful follow-up requests ask for the exact decision source and supply missing records. Asking for reconsideration in general terms is weaker than asking who decided, why, and what information was missing.

Steal these. They work because they ask for facts, not favors.

1 — After an automated screen-out

"The form screened me out before a clinician reviewed my history. My current BMI is ___ and my pretreatment BMI was ___. I've attached my prior prescription records. Can a licensed clinician review my full file and tell me whether a continuation review is available?"

2 — After a doctor says no

"I'm not asking for a guaranteed approval. I'd like to understand whether the decision was based on a specific safety concern, missing information, or your practice's policy on prescribing weight-management medication."

3 — Calling your insurance

"Please give me the exact denial reason, the denial code, your written coverage criteria, the appeal deadline, and the criteria for continuation as opposed to a new start."

4 — At the pharmacy counter

"What exact claim rejection message or code came back, and should my prescriber or my plan be the one to correct it?"

👉 Take all four with you

Use the one-page Second Look Packet below → No email gate. Copy it, fill it in, and take it to the next conversation.

What records should you gather before trying again?

Answer capsule: A second clinical review is only as good as the information it receives. The most useful file contains current and pretreatment measurements with dates, the original qualifying diagnosis, prior prescription and dose history, treatment response, relevant lab results, side-effect history, and the exact written rejection or denial notice.

Ten minutes of gathering beats another rejection.

For any second clinical opinion:

• Height, measured without shoes, and current weight, with today's date
• Your highest documented weight, with a date
• All medications and supplements
• Every diagnosis you actually have
• Allergies and any prior serious reactions
• Recent labs — A1C, lipids, anything relevant
• What you've already tried for weight
• The exact reason the first clinician gave

If you're continuing treatment you already started:

• Pretreatment BMI and the date it was recorded
• The original qualifying diagnosis
• When you started, and every dose since
• Pharmacy or prescription records
• Your weight trend
• Any related conditions that improved
• Side effects, and why treatment stopped if it did

If you're appealing insurance:

• The denial letter and denial code
• The plan's written criteria
• The formulary
• Diagnosis codes submitted
• Prior treatments tried, with dates and outcomes
• Your prescriber's supporting note
• The appeal deadline — this one is easy to miss and hard to undo

What never goes in the file: edited screenshots, a diagnosis you guessed at, a weight you entered to clear a line, or someone else's records.

Your one-page Second Look Packet

Copy this into a note or document. Leave a field blank rather than guessing.

Decision source: Intake form / clinician / insurer / pharmacy / unknown
Exact written reason or claim code:
Date of decision:
Current height, weight, and BMI with date:
Pretreatment weight and BMI with date, if continuing care:
Original qualifying diagnosis or weight-related condition:
Medication, start date, and dose history:
Prescription or pharmacy proof attached: Yes / No
Response to treatment:
Side effects or prior serious reactions:
Relevant labs or records attached:
The one question I need answered:
"Was this decision based on a label contraindication, a specific safety concern, missing information, platform policy, insurance criteria, or a pharmacy claim problem?"

When should you stop looking for another GLP-1 provider?

Answer capsule: Provider-shopping is not an appropriate response when a rejection identifies MTC or MEN 2, a serious allergy to the exact product, pregnancy-related risk, severe gastroparesis, a condition needing specialist oversight, or an unsafe weight-loss goal. A platform that approves treatment only because key history was hidden has not given you a safer answer.

There is no CTA in this section. That's deliberate.

Stop and talk to a specialist or the clinician who named the risk if:

• MTC or MEN 2 is in your personal or family history. This is the class-wide wall for Wegovy, Zepbound, and Foundayo. Go to the Open Door Map — different medicine classes may still be available.
• You've had a serious allergic reaction to a GLP-1 before. The exact drug that caused it is contraindicated. Another GLP-1 still needs explicit clinician review because the labels warn that cross-risk is unknown.
• You're pregnant, or trying. Current labels direct patients to stop when pregnancy is recognized. Wegovy also requires at least two months before a planned pregnancy. Talk to your OB about timing. This isn't forever — it's not now.
• You have severe gastroparesis. All three current labels compared here say not recommended. That is a specialist-level conversation, not a reason to look for a weaker screen.
• You have type 1 diabetes or complex insulin management. This is not a simple consumer eligibility question. Your endocrinology team answers it.
• You've had an eating disorder, or you're chasing a number rather than your health. If you're hiding what you're taking, or the goal weight keeps moving down, appetite-suppressing medication can make things worse. Coordinated care with someone who treats eating disorders comes first. The National Alliance for Eating Disorders runs a confidential, therapist-staffed referral helpline at 866-662-1235, Monday through Friday, 9 a.m.–7 p.m. Eastern. It is not a 24/7 crisis line; call or text 988 for crisis support.

Do not hide a diagnosis, a reaction, a pregnancy, or an eating-disorder history to get past a form. The details that trigger a rejection are usually the exact details a clinician needs to keep you safe. A yes you got by leaving something out isn't a yes. It's a gap in your chart.

Are compounded GLP-1s a way around the rules?

Answer capsule: No. Compounded prescription drugs still require a lawful clinical and pharmacy pathway. They are not FDA-approved finished products, so the FDA does not review them before sale for safety, effectiveness, or quality. Paying cash can remove an insurance barrier. It does not erase the medical history that caused a clinician or label-based no.

Let's define the word, because it gets thrown around loosely.

A compounded drug may be prepared by a state-licensed pharmacy under Section 503A for an identified patient with a valid prescription, or by an FDA-registered outsourcing facility under Section 503B under a different set of rules. The finished compounded product is not FDA-approved. It has not gone through the FDA's premarket review for safety, effectiveness, or quality the way an approved brand drug has.

Here's the part that matters for you today:

A medical "no" is not fixed by switching to a compounded product.

If a clinician declines you because of your history, that concern is about your history. A compounded product does not erase MTC or MEN 2, a serious allergy, pregnancy, severe gastroparesis, or another risk that caused the decision. A compounded product also does not have its own FDA-approved prescribing label that can be used as proof that the risk disappeared.

What cash pay and compounding can solve is a money no. If your plan will not cover treatment, paying cash removes the insurer from the transaction. That's real, and for some people it is the whole answer. It just is not a medical answer.

Where the law is right now: on April 30, 2026, the FDA proposed not adding semaglutide, tirzepatide, or liraglutide to the 503B bulks list, saying it had not found a clinical need for outsourcing facilities to compound them from bulk substances. The comment deadline was extended to July 30, 2026. We found no final Federal Register determination as of August 28, 2026. This proposal is about a specific 503B pathway; it is not a one-sentence ban on every lawful patient-specific compounded prescription.

FDA also states that semaglutide and tirzepatide are not currently on the 503B bulks list or the drug-shortage list. The legal ground is moving, and long-term availability can change.

Sources: FDA on 503A and 503B, FDA's compounded-drug risk statement, April 2026 proposal, comment-period extension, and FDA's current shortage-policy page.

If you do go the compounded route, verify all of this first:

• The name and state license of the prescribing clinician
• The full legal name of the dispensing pharmacy, checked against that state's board record
• Whether it is a 503A pharmacy or a 503B outsourcing facility, when relevant
• The exact medication, ingredient, concentration, and dosage form
• That the product is compounded, in writing
• The price after the intro period ends
• The renewal date and cancellation deadline
• The exact point at which the order becomes nonrefundable
• What happens to your money if a clinician declines you

And never: buy anything labeled "for research use only," mix powders yourself, use someone else's prescription, or order from a seller that ships without one. No-prescription access is a red flag, not a feature.

What we actually verified for this guide

Answer capsule: This page separates three kinds of claims: medical and regulatory facts from primary public documents, provider-stated commercial facts checked on each company's own pages with a date, and editorial routing judgments that are labeled as our judgment.

Medical and regulatory facts checked at the source:

• Section 4 contraindications and key warnings in the current labels for Wegovy, Zepbound, and Foundayo
• Foundayo's boxed-warning language and its April 1, 2026 FDA approval
• Contraindications and key warnings in the current labels for Contrave, Qsymia, and Xenical
• Thyroid cancer type distribution from the American Thyroid Association
• External-review scope and deadlines from HealthCare.gov and CMS
• KFF's 2024 HealthCare.gov claims-denial data
• Two historical 2025 Massachusetts appeal decisions and the January 2026 rule change that made the phentermine examples no longer current MassHealth criteria
• NIDDK guidance on long-term weight-management medication use
• FDA's April 2026 503B proposal, the July 30 comment deadline, and the lack of a final determination found by our August 28 check

Provider-stated commercial facts checked on each company's own site on August 28, 2026:

• Ro's $39 eligibility-refund statement, $74–$149 membership range, free coverage-report limits, and paid insurance-concierge workflow
• Sesame's three-hour cancellation window, no-refund rule after the first visit, prescription-discretion statement, and published Contrave and orlistat pages
• Yucca Health's temporary authorization hold, no-charge-if-no-prescription workflow, and compounded-medication disclosure
• Embody's medical-disqualification refund promise, its separate before-medication-is-ordered limit, and its transfer-of-care proof requirement

These are provider-stated facts, not outcomes we independently transaction-tested. We did not place a test order, request a refund, or confirm availability in every state.

Original decision tools assembled for this page:

• The five-source "no" framework
• The thyroid-type decision check
• The six-label Open Door Map
• The four-provider charge-and-refund comparison
• The rejection-to-next-step routing table
• The one-page Second Look Packet

What we did not verify, and won't claim:

• Whether you specifically qualify. Only a licensed clinician who reviews your record can say that
• Every provider's availability in every state
• Your plan's specific current criteria
• Whether any clinician will prescribe a particular medication
• Whether a price or policy will remain current after August 28, 2026
• That an FDA-listed warning is harmless merely because it is not in Section 4

Who we are: Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We earn a commission from some links on this page. That commission did not change a row in the Open Door Map, refund table, or routing table. The primary documents are linked so you can check them yourself.

Frequently asked questions

Can I get a GLP-1 online if one provider denied me? Possibly. If the decision came from an automated screen, missing record, practice policy, insurance rule, or pharmacy claim, another licensed review or a corrected submission may reach a different result. If MTC or MEN 2 applies, that closes Wegovy, Zepbound, and Foundayo. A serious allergy closes the exact drug and requires caution before considering another GLP-1.

Do all online providers use the same BMI rules? No. FDA-approved adult weight-management labels generally use BMI 30 or higher, or 27 or higher with a weight-related condition. Platforms can set stricter intake rules, continuation rules, age limits, state limits, or documentation requirements. A lower advertised floor is not proof that treatment is right for you.

Can I qualify at a BMI of exactly 27? The standard adult weight-management indication includes BMI 27 or higher with at least one documented weight-related condition, or 30 or higher on its own. At 27 without a documented condition, the usual labeled new-start answer is no. Get real screening rather than inventing a diagnosis.

Does a family history of thyroid cancer disqualify me? Only the thyroid type named in these labels: medullary thyroid carcinoma, or MEN 2. The American Thyroid Association says MTC is about 1%–2% of US thyroid cancers and up to 25% of MTC diagnoses are inherited. Find out which type your relative had and give that answer to a clinician.

Can I take a GLP-1 if I've had pancreatitis? A history of pancreatitis is not listed as a Section 4 contraindication in the current Wegovy, Zepbound, or Foundayo labels. Pancreatitis appears in warnings and requires a clinician to review the details. "Not a contraindication" is not the same as "automatically safe."

What can I take if I can't take a GLP-1? Contrave, Qsymia, and Xenical are FDA-approved for chronic weight management and do not carry the MTC or MEN 2 contraindication. Each has separate rules: Contrave is contraindicated with seizure disorders, chronic opioid use, uncontrolled high blood pressure, and MAOIs; Qsymia is contraindicated in pregnancy, glaucoma, hyperthyroidism, and recent MAOI use; Xenical is contraindicated in pregnancy, chronic malabsorption, and cholestasis.

Does an insurance denial mean I'm medically ineligible? No. It means your plan declined payment under its rules. A prescription can be medically appropriate and still be denied for prior authorization, step therapy, a benefit exclusion, a formulary rule, or missing paperwork.

Can I appeal an insurance denial for Wegovy or Zepbound? A denial involving medical judgment may go through internal appeal and then external review, depending on the plan and state. A pure benefit exclusion is usually a contract issue, so medical external review may not fit. Follow the instructions and deadline in your denial notice.

What does step therapy mean, and why did it get me denied? Step therapy means a plan requires a documented earlier treatment, exception, or reason that the preferred step is not appropriate. The exact rule changes by plan and date. Historical Massachusetts cases show how missing phentermine documentation caused denials, but MassHealth later removed that requirement. Use your plan's current written criteria, not an old example.

Will I get my money back if an online provider denies me? It depends on the company. Ro says it refunds the $39 first-month charge if you are not eligible. Yucca says it places a temporary hold and does not charge if no prescription is issued. Sesame does not refund the first month after the initial visit occurs. Embody's own policy contains conflicting language, so get its rule in writing before paying.

Does switching to a compounded product get around a medical no? No. A compounded product is not an FDA-approved finished drug, and it does not erase the health history that caused the decision. Cash pay removes the insurer. It does not remove MTC or MEN 2, a serious allergy, pregnancy, severe gastroparesis, or another clinical risk.

What if my state or provider requires a live or in-person visit? The clinician must be allowed to practice where you are located, and federal, state, medication, and platform rules all matter. Federal telemedicine flexibilities for controlled medications are extended through December 31, 2026 when their conditions are met, but that does not override state licensure, a platform's rules, or a clinician's judgment. The fix may be a live video visit or an in-person appointment.

Can I gain weight to qualify later? Please don't. It's not a strategy. It's a health risk. If your BMI is close to 27, get properly screened for real weight-related conditions. If your BMI fell because prescribed treatment worked, build a continuation file instead.

Can teenagers get a GLP-1? Some weight-management medications have adolescent indications and some do not. Criteria, dosing, growth, mental health, and family support make this a pediatric-clinician decision, not a consumer intake shortcut.

How do I check that an online prescriber and pharmacy are legitimate? Confirm the clinician's license with the state board where you are located. Get the pharmacy's full legal name and check its state board record. Require an actual prescription. Avoid anything labeled "research use only." Read renewal and refund terms before paying. Confirm in writing whether the finished product is FDA-approved or compounded.

One last thing

If you take nothing else from this page, take this: "you don't qualify" is not a sentence about your worth, your effort, or whether you deserve care. It's a sentence about a form, a clinician's judgment, a label, a contract, or a claim code. Four of those depend on one platform, review, plan, or pharmacy. That does not mean every no should change. It means you deserve to know which no you got.

Find out which one it was. Then take the one next step that matches it.

Still not sure which GLP-1 program is right for you?

Take our free two-minute matching quiz → You'll get a personalized action plan: insurance check, second opinion, continuation file, cash-pay comparison, non-GLP-1 conversation, or a stop-and-see-a-specialist result. No prescription promised — just a clear direction.

This page is educational and is not medical advice. It cannot tell you whether you qualify for any medication. Talk to a licensed clinician about your own health. If you are struggling with an eating disorder, the National Alliance for Eating Disorders can help with treatment referrals. Call or text 988 for immediate crisis support.